Summary
In the US, chronic low back pain affects about 28% of the population, and DDD is estimated to account for roughly half of specific CLBP cases, or around 14 million diagnosed prevalent cases in 2025.
Standard care includes pain relief, NSAIDs, physical therapy, lifestyle changes, injections, and surgery, but these approaches rarely restore disc structure or prevent further degeneration.
Cell-based regenerative therapies are gaining attention because they may reduce inflammation, support extracellular matrix repair, and activate endogenous healing within the disc microenvironment.
Several programs are advancing in lumbar DDD, including IDCT (DiscGen...
